ARTES Biotechnology has announced a collaboration with global pharmaceutical company, Boehringer Ingelheim Animal Health. ARTES Biotechnology specialises in recombinant protein production, process and vaccine development from microbial expression systems. ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
For the fifth time, the European PCV2 Research Award sponsored by Boehringer Ingelheim funds research projects related to Porcine Circovirus Type 2 (PCV2) infection and associated diseases. Nine high quality research proposals were submitted from seven different countries (UK, Italy, Spain, Sweden, Denmark, Estonia, and France).
Boehringer Ingelheim Vetmedica, Inc. (BIVI) is calling for proposal submissions for its annual Advancement in Porcine Reproductive and Respiratory Syndrome (PRRS) Research Award.
Boehringer Ingelheim Vetmedica, Inc. (BIVI) is inviting proposals for the annual Boehringer Ingelheim Advancement in PRRS Research Award Program.
Get the latest news on Swine Health Subscribe to our newsletter